The Cyber Resilience Act exclusions in Article 2 of Regulation (EU) 2024/2847 are narrower than most manufacturers expect. Medical devices, in vitro diagnostics, motor vehicles, certified aviation products, and national security/military items are explicitly excluded. Free and open-source software not placed on the market in the course of a commercial activity is also excluded under Article 2(6). Everything else — industrial IoT, consumer electronics, networking equipment, desktop and mobile software, firmware, embedded systems — is in scope. If your product has digital elements and a data connection, and it does not fall under one of the listed exclusions, you need the Art. 31 + Annex VII dossier. CRACheck generates it in 15–25 minutes. €149 per product.
€149 one-time payment per product · 8 PDF documents in ZIP · 15–25 minutes · 100% in your browser
Regulation (EU) 2024/2847 does not distinguish between consumer and industrial products. Article 2(1) covers any product with digital elements placed on the EU market with a data connection. Industrial IoT gateways, SCADA controllers, and building automation systems are in scope.
The Radio Equipment Directive is not listed in Art. 2(2) as an exclusion. Products under RED are subject to BOTH RED and the CRA. Article 12 addresses overlap — and Article 31(3) allows a single combined technical documentation set. The CRA adds cybersecurity requirements that RED does not cover.
Article 2(6) excludes only free and open-source software that is NOT placed on the market in the course of a commercial activity. If you distribute open-source software commercially — whether by selling it, bundling it with paid hardware, or providing paid support — the CRA applies to it.
If your product is not excluded, CRACheck generates the complete Art. 31 + Annex VII dossier.
Annex III / Annex IV classification. Conformity assessment module.
Art. 31 + Annex VII. Complete dossier.
Art. 13(2)–(3). Cybersecurity risk assessment against Annex I.
Annex II. 9 required information points.
Art. 28 + Annex V. Ready for signature.
Annex I Part II point (5). Coordinated vulnerability disclosure.
Art. 14. ENISA 24h/72h/14d notification.
Key dates and milestones.
See before you buy — Download sample dossier (PDF, fictional company) — Real structure, real articles, real format. Fictional data.
Generated in your browser. No data leaves your device.
CRACheck classifies your product against the CRA scope (Art. 2) and the Annex III/IV categories, and generates the complete Art. 31 + Annex VII dossier. If the Product Classifier determines your product is excluded, the report documents the legal basis for that exclusion.
CRACheck's Product Classifier provides a structured, regulation-based classification. It is not a binding legal opinion. If your product sits at the boundary of an exclusion (e.g., a connected device with both medical and consumer functions), consult specialised counsel.
CRACheck gives you the structured analysis and the documentation. A binding scope opinion, if needed, comes from a lawyer.
Art. 64(2) of Regulation (EU) 2024/2847.
Art. 64(3) of Regulation (EU) 2024/2847.
Art. 64(4) of Regulation (EU) 2024/2847.
| Criterion | Law firm scope opinion | Self-assessment (reading the OJ) | Industry association guidance | CRACheck |
|---|---|---|---|---|
| Scope determination | Written opinion | Your interpretation | General, not product-specific | Automated per Art. 2 + Annex III/IV |
| Documentation included | No | No | No | 8 PDFs per Art. 31 + Annex VII |
| Price | €3,000–€8,000 | €0 + internal hours | Free or membership fee | €149 per product |
| Time | 2–4 weeks | Days | N/A | 15–25 minutes |
Volume pricing: €99/product (pack 10), €79/product (pack 30). Run the Product Classifier first to confirm which SKUs require documentation.
Request Volume PricingCRACheck generates a structured document set according to Article 31 and Annex VII of Regulation (EU) 2024/2847 from the information you provide. The accuracy, completeness, and truthfulness of that information is your responsibility as the manufacturer.
We guarantee that the document structure follows Article 31 and Annex VII of Regulation (EU) 2024/2847 and that the legal references cited are correct. We do not guarantee that a specific document will be accepted by a market surveillance authority in a particular case.
CRACheck is not legal advice. For specific situations, consult a lawyer or specialised regulatory consultancy.